Iceni to repurpose Merck’s cilengitide | Chemical & Engineering News
Volume 94 Issue 23 | p. 15 | Concentrates
Issue Date: June 6, 2016

Iceni to repurpose Merck’s cilengitide

Department: Business
Keywords: drug development, cancer, therapy, cilengitide

Scottish DNA vaccines developer BigDNA has renamed itself Iceni Pharmaceuticals and relaunched to focus on repurposed cancer therapies. The firm’s lead candidate is cilengitide, a cyclic peptide. Cilengitide was initially developed by the Technical University of Munich and Merck KGaA, but it failed late-stage clinical trials for treating glioblastoma, an aggressive brain cancer. Iceni has demonstrated in preclinical trials that cilengitide is effective in a combination therapy for treating myeloma, a bone cancer. Iceni plans to begin Phase II trials in 2017.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment